Tags

Type your tag names separated by a space and hit enter

Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
Hum Vaccin Immunother 2015; 11(2):386-90HV

Abstract

To evaluate antibody response induced by trivalent inactivated influenza vaccine (TIV) against circulating influenza A (H3N2) strains in healthy adults during the 2010/11 and 2011/12 seasons, a hemagglutination-inhibition (HI) assay was utilized to calculate geometric mean antibody titer (GMT), seroprotection rate (post vaccination HI titers of ≥1 :40), and seroresponse rate (4-fold increase in antibody level). In the 2010/11 season, GMT increased 1.8- to 2.0-fold following the first dose of TIV against 3 circulating strains and 2.2-fold following the second compared to before vaccination. The seroresponse rate ranged from 22% to 26% following the first dose of TIV and from 31% to 33% following the second (n = 54). The seroprotection rate increased from a range of 6% to 13% to a range of 26% to 33% following the first dose of TIV and to a range of 37% to 42% following the second (n = 54). In the 2011/12 season, GMT increased 1.4-fold against A/Osaka/110/2011 and 1.8-fold against A/Osaka/5/2012. For A/Osaka/110/2011, the seroresponse rate was 29%, and the seroprotection rate increased from 26% to 55% following vaccination (n = 31). For A/Osaka/5/2012, the seroresponse rate was 26%, and the seroprotection rate increased from 68% to 84% following vaccination (n = 31). HI assays with reference antisera demonstrated that the strains in the 2011/12 season were antigenically distinct from vaccine strain (A/Victoria/210/2009). In conclusion, the vaccination increased the seroprotection rate against circulating H3N2 strains in the 2010/11 and 2011/12 seasons. Vaccination of TIV might have potential to induce reactive antibodies against antigenically distinct circulating H3N2 viruses.

Authors+Show Affiliations

a Department of Infectious Diseases ; Osaka Prefectural Institute of Public Health ; Osaka , Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25692378

Citation

Hiroi, Satoshi, et al. "Trivalent Influenza Vaccine-induced Antibody Response to Circulating Influenza a (H3N2) Viruses in 2010/11 and 2011/12 Seasons." Human Vaccines & Immunotherapeutics, vol. 11, no. 2, 2015, pp. 386-90.
Hiroi S, Morikawa S, Nakata K, et al. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons. Hum Vaccin Immunother. 2015;11(2):386-90.
Hiroi, S., Morikawa, S., Nakata, K., Maeda, A., Kanno, T., Irie, S., ... Kase, T. (2015). Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons. Human Vaccines & Immunotherapeutics, 11(2), pp. 386-90. doi:10.1080/21645515.2015.1009338.
Hiroi S, et al. Trivalent Influenza Vaccine-induced Antibody Response to Circulating Influenza a (H3N2) Viruses in 2010/11 and 2011/12 Seasons. Hum Vaccin Immunother. 2015;11(2):386-90. PubMed PMID: 25692378.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons. AU - Hiroi,Satoshi, AU - Morikawa,Saeko, AU - Nakata,Keiko, AU - Maeda,Akiko, AU - Kanno,Tsuneji, AU - Irie,Shin, AU - Ohfuji,Satoko, AU - Hirota,Yoshio, AU - Kase,Tetsuo, PY - 2015/2/19/entrez PY - 2015/2/19/pubmed PY - 2015/12/17/medline KW - ACIP, Advisory Committee on Immunization Practices KW - EMA, European Medicines Agency KW - GMT, geometric mean antibody titer KW - H3N2 KW - HI, hemagglutination-inhibition KW - TIV, trivalent inactivated influenza vaccine KW - antibody KW - circulating viruses KW - influenza KW - vaccine SP - 386 EP - 90 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 11 IS - 2 N2 - To evaluate antibody response induced by trivalent inactivated influenza vaccine (TIV) against circulating influenza A (H3N2) strains in healthy adults during the 2010/11 and 2011/12 seasons, a hemagglutination-inhibition (HI) assay was utilized to calculate geometric mean antibody titer (GMT), seroprotection rate (post vaccination HI titers of ≥1 :40), and seroresponse rate (4-fold increase in antibody level). In the 2010/11 season, GMT increased 1.8- to 2.0-fold following the first dose of TIV against 3 circulating strains and 2.2-fold following the second compared to before vaccination. The seroresponse rate ranged from 22% to 26% following the first dose of TIV and from 31% to 33% following the second (n = 54). The seroprotection rate increased from a range of 6% to 13% to a range of 26% to 33% following the first dose of TIV and to a range of 37% to 42% following the second (n = 54). In the 2011/12 season, GMT increased 1.4-fold against A/Osaka/110/2011 and 1.8-fold against A/Osaka/5/2012. For A/Osaka/110/2011, the seroresponse rate was 29%, and the seroprotection rate increased from 26% to 55% following vaccination (n = 31). For A/Osaka/5/2012, the seroresponse rate was 26%, and the seroprotection rate increased from 68% to 84% following vaccination (n = 31). HI assays with reference antisera demonstrated that the strains in the 2011/12 season were antigenically distinct from vaccine strain (A/Victoria/210/2009). In conclusion, the vaccination increased the seroprotection rate against circulating H3N2 strains in the 2010/11 and 2011/12 seasons. Vaccination of TIV might have potential to induce reactive antibodies against antigenically distinct circulating H3N2 viruses. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/25692378/Trivalent_influenza_vaccine_induced_antibody_response_to_circulating_influenza_a__H3N2__viruses_in_2010/11_and_2011/12_seasons_ L2 - http://www.tandfonline.com/doi/full/10.1080/21645515.2015.1009338 DB - PRIME DP - Unbound Medicine ER -